7 terminated. 7 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 7 |
| Phase 3 | 1 | Terminated 1 |
Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PR3-AAV Resilient Remission or PRRR Obinutuzumab, Rituximab - Granulomatosis With Polyangiitis, Microscopic Polyangiitis | Phase 2 | Terminated | Mayo Clinic | 6 | 2023-06-30 | 2026-05-06 |
| Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis Rituximab, Infliximab, Tocilizumab - Giant Cell Arteritis, Takayasu Arteritis | Phase 2 | Terminated | Cambridge University Hospitals NHS Foundation Trust | 22 | 2021-07-14 | 2025-06-17 |
| Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA IFX-1 low dose, IFX-1 high dose, Placebo - Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA) | Phase 2 | Terminated | InflaRx GmbH | 20 | 2018-10-15 | 2022-05-26 |
| Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis rituximab, Prednisone, Placebo - Cryoglobulinemia, Systemic Vasculitis | Phase 2 | Terminated | Assistance Publique - Hôpitaux de Paris | 14 | 2015-07-17 | 2019-03-18 |
| Abatacept in ANCA Associated Vasculitis Abatacept (Orencia) - ANCA-associated Vasculitis | Phase 2 | Terminated | Imperial College London | 7 | 2007-11-01 | 2015-05-29 |
| Rituxan in Churg Strauss Syndrome With Renal Involvement Rituximab, Prednisone - Churg-Strauss Syndrome | Phase 2 | Terminated | Fernando Fervenza | 4 | 2007-06-01 | 2011-12-08 |
| Plasma Exchange for Renal Vasculitis Plasma exchange, Intravenous methyl prednisolone, Methyl prednisolone - Wegener's Granulomatosis, Microscopic Polyangiitis | Phase 2 / Phase 3 | Terminated | Cambridge University Hospitals NHS Foundation Trust | 150 | 1995-03-01 | 2011-08-03 |
Granulomatosis with Polyangiitis (4) · Microscopic Polyangiitis (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Churg-Strauss Syndrome (2) · Vasculitis (2) · Cogan Syndrome (1) · Cryoglobulinemia (1) · Cryoglobulinemia, Familial Mixed (1) · Giant Cell Arteritis (1) · Glomerulonephritis (1) · IgA Vasculitis (1) · Polyarteritis Nodosa (1) · Polychondritis, Relapsing (1) · Takayasu Arteritis (1)
Cardiovascular Diseases (7) · Immune System Diseases (7) · Skin Diseases (7) · Skin Diseases, Vascular (7) · Skin and Connective Tissue Diseases (7) · Vascular Diseases (7) · Autoimmune Diseases (6) · Brain Diseases (5) · Central Nervous System Diseases (5) · Cerebrovascular Disorders (5) · Nervous System Diseases (5) · Vasculitis (5) · Cerebral Small Vessel Diseases (4) · Hemic and Lymphatic Diseases (4)
Rituximab (4) · Prednisone (2) · Abatacept (1) · Infliximab (1) · Plasma Exchange (1) · obinutuzumab (1) · tocilizumab (1) · vilobelimab (1)
Cambridge University Hospitals NHS Foundation Trust (2) · Assistance Publique - Hôpitaux de Paris (1) · Fernando Fervenza (1) · Imperial College London (1) · InflaRx GmbH (1) · Mayo Clinic (1)
United Kingdom (3) · United States (3) · Canada (1) · France (1)
Alan Salama (1) · David Jayne (1) · Fernando C. Fervenza, M.D., Ph.D. (1) · Korinna Pilz, MD, MS (1) · Niels Rasmussen, MD (1) · Peter A. Merkel, MD, MPH (1) · Ulrich Specks, MD (1)
PMID 21325353, PMID 23615499, PMID 33164993
UL1RR024150 (1)